Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes

NCT00376181 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT00376181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00376181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2006
Completion date
May 31, 2007
Enrollment
96 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes